14 results about "Topical anesthetic" patented technology

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The invention relates to the technical field of oral anesthesia, in particular to an oral hydrogel topical anesthesia patch and a preparation method thereof. The hydrogel surface anesthesia patch comprises a composite hydrogel base material and an anesthetic loaded on the composite hydrogel base material, the novel composite hydrogel comprises the following components in percentage by mass: 8%-15% of sodium carboxymethyl cellulose, 4%-8% of hyaluronic acid, 6%-12% of polyvinyl alcohol, 4%-9% of quaternized modified chitosan, 3%-7% of poly gamma-glutamic acid, 2%-6% of an adhesion regulator, 2%-5% of a humectant, 0.5%-2% of a cross-linking agent and a proper amount of water. The anesthetic is lidocaine or tetracaine, and the mass fraction of the anesthetic in the oral hydrogel topical anesthesia patch is 2%-8%. According to the invention, quaternized modified chitosan and poly gamma-glutamic acid are taken as core functional components, and a novel composite hydrogel base material system of sodium carboxymethyl cellulose, hyaluronic acid and polyvinyl alcohol is combined, so that the application property and slow release property of the surface anesthesia patch are ensured.

A novel ophthalmic treatment for ocular pain, such as epithelial defects of the cornea or conjunctiva, which includes a liquid or gel-based formulation containing a topical anesthetic mixed with an antibiotic. The two substances are combined according to a preferred volumetric ratio wherein the anesthetic retains its efficacy in alleviating the patient's pain, while also diluting the anesthetic enough to permit patients to self-administer the eyedrops without clinical supervision. In a preferred example, the antibiotic comprises moxifloxacin (or an equivalent fluoroquinolone-class antibiotic) at an initial concentration of about 0.5%, and the anesthetic comprises proparacaine hydrochloride at an initial concentration of about 0.5%. Preferably, the volumetric ratio of the antibiotic and an excipient relative to the anesthetic is between about 5:1 and about 15:1, such that the antibiotic and the excipient dilute the anesthetic down to a relative concentration of about 0.030% to about 0.085%.

The invention provides a surface anesthetic with oral mucosa adhesiveness and salivation resistance and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises lidocaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

A method for constructing a graded limbal injury and repair model comprises: after administering topical anesthetic drops to the operated eye of a model animal, placing a limbal injury device containing a NaOH solution in the limbal area of ​​the model animal for 30 seconds, then removing the device and irrigating the operated eye with saline; postoperatively, administering an antibacterial drug to the operated eye of the model animal several times daily; and eight days after surgery, a graded limbal injury and repair model is obtained, wherein the limbal injury device applies alkali burns of varying sizes to the limbal area, thereby achieving a graded injury effect. The construction method provided by the present invention has been shown to be simple, laboratory-friendly, inexpensive, short, and reproducible, with quantifiable evaluation methods, making it an ideal method for constructing an animal model of limbal stem cell injury.

A novel ophthalmic treatment for corneal abrasions includes a liquid eyedrop containing a topical anesthetic mixed with an antibiotic. The two substances are combined according to a preferred volumetric ratio wherein the anesthetic retains its efficacy in alleviating the patient's pain, while also diluting the anesthetic enough to permit patients to self-administer the eyedrops without clinical supervision. In a preferred example, the antibiotic comprises moxifloxacin (or an equivalent fluoroquinolone-class antibiotic) at an initial concentration of about 0.5%, and the anesthetic comprises proparacaine hydrochloride at an initial concentration of about 0.5%. Preferably, the volumetric ratio of the antibiotic to the anesthetic is between about 5:1 and about 15:1, such that the antibiotic dilutes the anesthetic down to a relative concentration of about 0.030% to about 0.085%.

To provide formulations for providing pain relief in humans and animals by administering a preservative-free intranasal dose of a local anesthetic formulation for the treatment of tri-geminal neuralgia, facial neuropathic pain, facial cancer induced neuropathic pain, migraine pain, and cluster headache pain.SOLUTION: A nasal spray formulation comprises from about 5% to about 30% w / v of a locally active sodium channel blocker, from about 0.25% to about 5% w / v of a buffering agent, and from about 5% to about 99% w / v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, and the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a certain amount of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.SELECTED DRAWING: None

The invention provides a surface anesthetic with oral mucosa adhesiveness, salivation resistance and taste improvement effects and a preparation method of the surface anesthetic, and belongs to the technical field of anesthetics. The surface anesthetic provided by the invention comprises tetracaine hydrochloride, glycopyrronium bromide and an auxiliary material, and the auxiliary material comprises a drug entrapment auxiliary material. Compared with caine anesthetics used clinically, the surface anesthetic provided by the invention has multiple functions of salivation resistance, good mucous membrane adhesiveness and improved taste, not only improves the drug effect, but also increases the medication compliance, and has great clinical application value.

Devices, groups of devices, kits, and methods for using the devices and kits to administer a local anesthetic to a port site to numb the site prior to infusion or blood draw are described. The devices contain a flexible material with an adhesive coating on one side and a compartment for containing the medication. The device can be pre-filled or a fillable device. In fillable devices, the local anesthetic is transferred from a container into the compartment of the device via the inlet after the device is applied to the patient's skin. In pre-filled devices, the local anesthetic is inside the compartment and is covered with a removable layer to keep it sterile until use. When applied to the patient's skin, the device conforms to the surface of the patient's skin forming a seal keeping the medication in contact with port site.

A cytotoxic agent and its use in dehorning an animal or inhibiting horn growth in a young animal. The cytotoxic agent may be a hardener, a p53 activator, an antiprotozoal agent, an apoptosis inducer, or a local anesthetic.

To provide a composition for external use which is an emulsion and suppresses separation between a water phase and an oil phase.SOLUTION: There is provided a composition for external use which comprises an antihistaminic agent and a vegetable oil and is an emulsion. The antihistaminic agent preferably is diphenhydramine or a salt thereof and the essential oil preferably is lavender oil and eucalyptus oil. Furthermore, the composition may contain a topical anesthetic. The emulsion preferably is an oil-in-water type. The composition may contain 1 to 95 wt.% of water, based on the total amount of the composition.SELECTED DRAWING: None

This invention discloses a traditional Chinese medicine composition for improving acne, consisting of Platycodon grandiflorus, Citronella rotundus, Taraxacum mongolicum, Angelica dahurica, Angelica sinensis, fermented soybean, Prunus persica, and Saffron. Studies have shown that anti-inflammatory Western medicines, heat-clearing and cooling traditional Chinese medicines, and topical anesthetic acne-removing drugs can constrict visceral capillaries or inhibit skin heat dissipation nerves, causing the body's heat to be unable to dissipate normally. This leads to increased heart rate and abnormally increased facial blood flow through hypothalamic regulation, compensating for heat loss and forming acne, while also increasing the burden on the heart. Long-term renal capillary constriction can also disrupt bone marrow hematopoietic homeostasis and increase the risk of leukemia. Platycodon grandiflorus, Citronella rotundus, Taraxacum mongolicum, Angelica sinensis, and Prunus persica can dilate visceral microvessels; Angelica dahurica bidirectionally regulates skin-visceral blood flow; fermented soybean stabilizes the body temperature center; and Saffron, within a safe dosage of 0.5-2 parts, bidirectionally regulates microvessels, achieving anti-inflammatory effects on the face, heat dissipation in the internal organs, and kidney protection and detoxification. This invention combines various drugs to dilate visceral blood vessels, stabilize central body temperature regulation, and suppress compensatory heart rate and facial congestion, thereby improving acne and acne scars from the root cause. It also protects the heart, kidneys, and blood system. The medicine is mild and can be taken for a long time. It is hormone-free, does not cause drug resistance, and is not prone to recurrence, making it suitable for industrial application.

An apparatus for dispensing topical anesthetic is described. The apparatus includes a pouch, a cover material, and a topical anesthetic. The pouch includes a containing material, and the pouch contains the topical anesthetic. A method of administering topical oral anesthetic using the pouch is also described.

A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesthetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.